Full-Time
Lead Engineer
IAM Platform Engineering
Updated on 9/12/2026
Cencora
10,001+ employees
Global pharmaceutical distribution and services provider
No salary listed
Pune, Maharashtra, India
In Person
Bachelor's, Master's
 Cybersecurity (1) |
|---|
Get referred to Cencora
See people who can refer or advise you
- A bachelor's degree in computer science, information technology, cybersecurity, software engineering, or a related field, or equivalent experience is required.
- At least 6 years of experience in platform engineering, identity and access management, software development, systems administration, or a related field is required.
- Lead the strategic design and continuous evolution of enterprise-scale identity platforms to ensure resilient, highly secure user authentication globally.
- Formulate automated deployment pipelines and complex application programming interface integrations to standardize secure access across major digital transformation initiatives.
- Analyze platform telemetry and security logs to engineer proactive defense mechanisms that address systemic architectural vulnerabilities.
- Advise senior technology leadership on the structural capabilities required to support long-term corporate cloud migrations and compliance mandates.
- Resolve critical tier-four platform outages and high-stakes identity disruptions by engineering structural remediations and system-hardening protocols.
- Evaluate emerging identity technologies and zero-trust frameworks to authorize strategic technical investments for the platform engineering organization.
- A master's degree in computer science, information technology, cybersecurity, software engineering, or a related field, or equivalent experience is preferred.
- A certification in cybersecurity, cloud infrastructure, or an equivalent area is preferred.
Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.
Company Size
10,001+
Company Stage
IPO
Headquarters
Pennsylvania
Founded
1907
Get referred to Cencora
See people who can refer or advise you
Simplify's Take
What believers are saying
- Fiscal 2026 Q3 revenue reached $84.8 billion, and EPS guidance rose to $17.75-$17.95.
- Cencora completed OneOncology in February 2026, strengthening specialty-pharmacy and oncology economics.
- A $7 billion revolver and $1 billion buyback show lenders and management backing execution.
What critics are saying
- Opioid litigation still carries a $4.2 billion accrued liability through 2039.
- Maryland courts vacated Baltimore's $152 million verdict, but appeals can revive distributor exposure.
- ASP rule changes and 340B guidance threaten community-oncology margins by 2028, hitting OneOncology.
What makes Cencora unique
- Cencora pairs drug distribution with OneOncology, deepening specialty-care workflow integration.
- Its global network spans U.S. Healthcare Solutions and International Healthcare Solutions across 51,000 employees.
- Nucleus inventory tools and cell-gene therapy enablement embed Cencora inside provider operations.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Paid Parental Leave
Adoption Assistance
Infertility Coverage
Family Planning Benefits
Behavioral Health Solutions
Professional Development Budget
Training Programs
Company News
Cencora has launched Cell and Gene Therapy Enablement through its Accelerate Pharmacy Solutions division to help health systems develop and expand cell and gene therapy programmes. The service provides support across financial planning, operational readiness, and scalable growth to reduce care barriers and improve patient access to advanced therapies. More than 35 cell and gene therapies have received FDA approval, with over 1,700 clinical trials underway globally. However, only 4% of health system pharmacy leaders report being fully prepared to integrate these treatments, highlighting infrastructure gaps. The offering includes market assessments, readiness evaluations, governance design, and workflow planning. Cencora, ranked number 10 on the Fortune 500 with over $300 billion in annual revenue, already provides specialty pharmaceutical services across the therapy lifecycle.
Cencora reported second-quarter revenue of $84.75 billion, slightly above analyst estimates of $84.43 billion, representing 5.1% year-on-year growth. Adjusted earnings per share came in at $4.48, beating consensus estimates of $4.35 by 3%. Management attributed the performance to strength in specialty pharmaceuticals, particularly through Management Services Organisations like OneOncology and RCA. CEO Robert Mauch highlighted the company's positioning in specialty care, stating, "Our specialty platform supports growth across the healthcare ecosystem." The company raised its full-year adjusted EPS guidance to $17.85 at the midpoint. Operating margin held steady at 1.3%, matching the same quarter last year. During the earnings call, analysts questioned management about biosimilar opportunities, specialty logistics competition, and potential policy risks from proposed ASP rule changes.
Cencora reported strong third-quarter results for fiscal year 2026, driven by execution across its business units and investments in its specialty positioning. The pharmaceutical distributor achieved double-digit adjusted operating income growth and 12% earnings per share growth in the quarter. The company conducted $1 billion in opportunistic share repurchases during the period. Based on its performance and confidence in continued execution, Cencora raised its fiscal 2026 EPS guidance. President and CEO Robert Mauch credited the results to the company's team members and their commitment to providing solutions for customers. He highlighted the strength of Cencora's portfolio and its pharmaceutical-centric strategy as the company approaches the end of its fiscal year. The earnings call was held on 5 August 2026, with senior leadership including Mauch and CFO Eva Boratto participating.
Cencora and its subsidiary Innomar Strategies have amended their credit agreement, increasing their multi-currency revolving credit facility from $5.5 billion to $7.0 billion. The facility's maturity date has been extended to July 2031. Interest rates on borrowings range from 69.5 to 110 basis points over various term rates, depending on Cencora's public debt ratings. The agreement includes covenants such as a maximum financial leverage ratio. Separately, on 31 July 2026, Cencora amended its receivables securitisation facility, reducing it from $1.5 billion to $1.0 billion whilst increasing the accordion feature from $500 million to $1.0 billion. This gives the company the option to expand commitments by up to $1.0 billion, subject to bank approval.
Wall Street analysts expect Cencora to report quarterly earnings of $4.37 per share, marking a 9.3% year-over-year increase. Revenues are projected to reach $84.89 billion, up 5.2% from the same quarter last year. Over the past 30 days, the consensus earnings per share estimate has been revised upward by 1.3%. Analysts forecast revenue from Total US Healthcare Solutions at $75 billion, representing 2.9% year-over-year growth. International Healthcare Solutions revenue is expected to remain flat at $7.79 billion. Operating income projections show US Healthcare Solutions at $940.87 million and International Healthcare Solutions at $158.45 million. Cencora shares have risen 5.3% over the past month and hold a Zacks Rank of 2, indicating expected outperformance versus the broader market.